Climb Bio, Inc. Stock: price and insider trades · United States

Every trade that managers of Climb Bio, Inc. disclose to SEC (Form 4) is tracked on this page. Between 18 October 2025 and 18 October 2026, 5 insiders published 13 filings.

Purchases and sales both appear in the filings: 1 purchase (1 insider, €21k) and 4 sales (2 insiders, €1.8M). The totals exclude 1 filing filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a sale of €1.2M from Thomas Stephen Basil, disclosed on 17 September 2026, or 0.20% of market capitalisation. The buyers include 1 senior executive.

Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 13 filings, this issuer sits below that mark. Since 2021, the database holds 1 purchase and 13 sales by insiders of the company.

The latest purchase dates back some time: it was published 284 days ago, on 7 January 2026. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.